Testing cardiovascular drug safety and efficacy in randomized trials

Area of Science:

• Clinical Pharmacology
• Biostatistics
• Drug Development

Background:

• Randomized trials (RCTs) are crucial for approving new therapeutics, providing unbiased efficacy and risk estimates.
• Concerns exist regarding the generalizability of RCT findings due to unrepresentative populations and controlled conditions.
• Average trial results may obscure significant interindividual variations in drug response.

Purpose of the Study:

• To examine why large Phase 3 trials, despite being costly, may not fully address unmet medical needs.
• To discuss the limitations of RCTs in reflecting real-world clinical practice and patient heterogeneity.
• To explore the gap between establishing drug efficacy in trials and demonstrating effectiveness in diverse patient populations.

Main Methods:

• Review of existing literature and methodologies in clinical trial design and analysis.
• Discussion of the distinction between efficacy (controlled settings) and effectiveness (real-world settings).
• Exploration of strategies for individualizing risk and treatment benefit estimation.

Main Results:

• RCTs provide average treatment effects but may not capture the full spectrum of patient responses.
• Controlled trial conditions (e.g., drug dosage, concomitant medications) differ from real-world practice.
• Individualized risk estimates are being developed to complement trial data.

Conclusions:

• Large RCTs, while essential for regulatory approval, may have limitations in addressing diverse patient needs.
• The transition from efficacy to effectiveness requires careful consideration of real-world factors.
• Further research is needed to bridge the gap between trial findings and personalized patient care.